English Synonyms
Cs-274;aprepitant(Mk-0869,L-754030);5-[[(2r,3s)-2-[(1r)-1-[3,5-Bis(Trifluoromethyl)phenyl]ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]methyl]-1,2-Dihydro-3h-1,2,4-Triazol-3-One;emend;mk-0869;5-[[(2r,3s)-2-[(1r)-1-[3,5-Bis(Trifluoromethyl)phenyl]ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]methyl]-1,2-Dihydro-3h-1,2,4-Triazol-3-One L)phenyl]ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]methyl]-1,2-Dihydro-3h-1,;5-[[(2r,3s)-2-[(1r)-1-[3,5-Bis(Trifluoromethyl)phenyl]ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]methyl]-1,2-Dihydro-3h-1,2,4-Triazol-3-One,Emend;aprepitant(Mk-0869)
Aprepitant Properties
| Melting point | 244-246°C |
| Specific rotation | D25 +69° (c = 1.00 in methanol) |
| Density | 1.51±0.1 g/cm3(Predicted) |
| Storage conditions | Sealed in dry,2-8°C |
| Solubility | Dissolved in DMSO (>25mg/ml) |
| Acidity coefficient (pKa) | 8.06±0.20(Predicted) |
| Form | Powder |
| Color | White to beige |
| Optical activity | [α]/D +61 to +71°, c = 1.0 in methanol |
| Stability | Solutions in DMSO can be stored at -20°C for up to 3 months. |
Overview
Aprepitant Was Approved for Marketing in the United States and the European Union in 2003 for Combined Administration with Other Antiemetic Drugs to Prevent Acute or Delayed Nausea and Vomiting During the Initial or Repeated Treatment of Highly or Moderately Emetogenic Tumor Chemotherapy. It Has Been Approved in More Than 75 Countries. The Drug Blocks the Action of Substance P by Binding to Nk-1 Receptors (Mainly Present in the Central Nervous System and Its Periphery), And Can Pass Through the Blood-Brain Barrier and Occupy Nk-1 Receptors in the Brain. It Has Selectivity and High Affinity, While Its Affinity for Nk-2 and Nk-3 Receptors Is Very Low. At the Same Time, It Also Has Low Affinity for the Targets of Other Drugs Used to Treat Chemotherapy-Induced Nausea and Vomiting Symptoms (Such as Dopamine Receptors and 5-Ht Receptors), And Its Effect in Reducing Nausea and Vomiting Is Better Than Other Drugs.
Uses
Antitumor Drugs
Uses
Preventing Chemotherapy-Related Nausea and Vomiting
Production Method
2-(R)-[1-(R)-[3,5-Bis(Tetrafluoromethyl)phenyl]ethoxy]-3-(S)-(4-Fluorophenyl)morpholine(R) Camphorsulfonate and Potassium Carbonate Are Dissolved in Dimethylformamide, And a Dimethylformamide Solution of 3-Chloromethyl-1,2,4-Triazolin-5-One Is Added at 22°c, Stirred, Water Is Added, And Cooled in an Ice Bath. The Crystals Are Collected by Filtration, Washed with Water, And Dried to Obtain Aprepitant.
